Redica 2026 年 10 月法规回顾:FDA 指南定稿与草案、欧盟药品法规一读文本及 Annex 1 联合解读发布
The Redica Regulatory Review: October 2026
Redica 2026 年 10 月法规回顾汇总 12 项进展,含 FDA 多份指南定稿与草案、欧盟药品法规一读文本刊发及 Annex 1 联合解读生效。其中处方药相关软件标签指南自 10 月 20 日起生效,生物类似药及可互换生物类似药上市后变更问答自 10 月 9 日起生效。仍开放征求意见的草案截止时间分布在 2026 年 11 月 7 日至 2027 年 1 月 31 日之间。

Several questions regulatory teams have carried since 2023 or 2024 had their answers concretely finalized this October. FDA finalized its 2023 draft on prescription drug software and its 2024 draft on biosimilar manufacturing changes, and PIC/S, EMA and WHO adopted a joint interpretation of the 2022 sterile Annex 1. The Council published its adopted pharmaceutical package texts with its reasons, Great Britain decided that CE-marked devices stay on its market indefinitely, and Health Canada set December 1 for revised establishment licensing. A second group of documents opens rules for products and methods that current frameworks handle poorly, from a single BLA covering individualized genome editing variants and confirmatory platform trials in the EU to rare disease and pediatric exclusivity in China, device delivery performance under QMSR, AI scribes in Australia and the adaptive AI device regime in the MHRA’s 2030 strategy. Labeling, CMC and device teams can plan against the settled items now and still shape the open drafts, whose comment windows run from November 7, 2026 to January 31, 2027.
1. FDA Finalizes How Drug Labeling Rules Apply to Sponsor Software
Final | Digital Health
Software output that demonstrates meaningful clinical improvement becomes FDA-required labeling, and promotional output goes on Form FDA 2253. Final guidance in effect since October 20, 2026.
Substance
The final guidance explains how FDA applies its drug labeling authorities to end-user output from software disseminated by or on behalf of a sponsor, and now states expressly that software from a developer working under agreement with the sponsor is in scope. Output becomes FDA-required labeling when the software is essential to safe and effective use or when it demonstrates a meaningful improvement in a clinical outcome, a standard that now applies to standalone functions as well as device-connected ones. FDA recommends adequate and well-controlled studies comparing drug use with and without the software to support that claim, described in the Prescribing Information, and a PI statement when use of the software is not necessary for safe and effective use. Optional device-connected functions generally warrant a brief PI description, and device-connected software should be shown to handle data and display output without creating medication errors. Promotional output is submitted on Form FDA 2253 at initial dissemination under a new PDURS material type, earlier for accelerated-approval products, with no resubmission when an update leaves output unchanged. A labeling decision tree replaces the former Appendix A.
Significance
The final replaces the September 2023 draft, and its revised clinical-benefit wording, the formally defined standalone category and the broader combination product definition, which now reaches biologic-device and three-constituent products, are changes sponsors could not plan around until October. Ropes & Gray and other law firms published client alerts within days, focusing on how the meaningful-improvement pathway treats output as required labeling even where the software is not essential, and on the open question of software that mixes disease-awareness and PDURS functions. FDA also posted a memorandum outlining its approach to end-user output to the docket. Certain postapproval changes to output that is FDA-required labeling are subject to FDA review and approval under the applicable application requirements, which ties software release cycles to labeling change procedures.
Redica Recommendation
Drug and combination product sponsors should inventory every app and software function disseminated by them or on their behalf, classify each as device-connected or standalone, and identify which outputs now need Prescribing Information language or a Form FDA 2253 submission before the next software release.
Reference document: Regulatory Considerations for Prescription Drug Use Related Software - Guidance for Industry - October 2026 <RDR500019394>
2. FDA Proposes a Single BLA for Many Individualized Genome Editing Variants
Draft | Cell & Gene Therapy
New patient-tailored variants inside an approved individualized feature space would be added by supplement as manufacturing changes. Comments due November 27, 2026.
Substance
The draft guidance lets an applicant submit multiple patient-tailored genome editing product variants in one BLA, limited to monogenic diseases caused by known pathogenic variants where every variant achieves the same editing outcome. It introduces the individualized feature space (IFS), the allowable limits of variation for features such as guide RNA spacer sequences or editor options, within which a new variant counts as a manufacturing change. Applicants would justify IFS boundaries mainly with clinical data from studied variants, supported by in vitro data, and set in vitro safety and activity criteria, including off-target editing limits and an on-target acceptance criterion, that every variant must meet. Manufacturing, specifications and process validation must cover every variant, with variant-specific identity testing, chain-of-identity procedures for ex vivo products and qualification runs bracketing the smallest and largest batch scales. Lot-release potency assays should measure the contribution of the variable features, and each guide RNA and editor combination needs in vitro off-target assessment by predefined next-generation sequencing, with the protocol filed in the BLA. Variants within an established IFS are added through supplements, preferably under an approved postapproval change management protocol; IFS expansions need a prior approval supplement and a new editing mechanism needs a new BLA. All variants share one proprietary name, one nonproprietary name and one NDC.
Significance
At CBER's launch webinar, the agency described the current practice of treating each individualized variant as a separate product with its own development program and BLA, the practice this draft would change. RAPS and other trade outlets placed it in a sequence of CBER drafts this year, including the February plausible mechanism draft, the April draft on next-generation sequencing for off-target assessment and the June draft on prior knowledge, and noted that it was issued alongside an HHS and CMS announcement expanding the Cell and Gene Therapy Access Model. Trade coverage also observed that adding variants shifts the evidence burden toward CMC assay data, since in vitro data carry new variants once the IFS is set. The Federal Register notice of October 28 allows only 30 days for comment, so developers have little time to test the IFS concept against their own platforms.
Redica Recommendation
Genome editing developers with patient-tailored programs should decide whether their guide RNA and editor variation can be bounded as an individualized feature space, and submit comments on the clinical-data basis FDA proposes for setting those bounds by November 27, 2026.
Reference document: Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management - Draft Guidance for Industry - October 2026 <RDR500019689>
3. FDA Rewrites Its Drug Delivery Device Performance Draft Around QMSR
Draft | Combination Products
Revision 1 replaces essential drug delivery outputs with essential performance characteristics and aligns verification and controls with QMSR. Comments due January 28, 2027.
Substance
The revised draft defines essential drug delivery device performance characteristics (EDDCs) as system-level, device-design-dependent characteristics needed to deliver the intended dose to the intended site, and excludes underlying component attributes, unrelated safety functions and functions that depend on user actions. A direct explanation with annotated product examples replaces the earlier stepwise filtering of design outputs, the framework now cites the QMSR and incorporated ISO 13485 requirements in place of 21 CFR 820.30, and ISO 11608 primary functions and EDDCs are stated not to coincide necessarily. Verification recommendations add justification of lot numbers with attention to lot-to-lot variability, testing of the finished product, and sequential preconditioning for high-risk, environmentally sensitive products beyond emergency-use injectors. Specification justification is separated from validation, with literature, anthropometric data and simulated bench testing placed under specification development. Control strategies may rely on upstream controls, downstream controls or both where justified. Submissions should carry EDDC- specific protocols, test reports, clinically meaningful acceptance criteria and risk-management documentation, and changed specifications need new verification, including stability and preconditioning information, or a justification for reusing existing evidence.
Significance
The revision replaces the 2024 Essential Drug Delivery Outputs draft and was issued jointly by the Office of Combination Products, CDER, CBER and CDRH, so it governs review across drug-led and device-led submissions. Commentary on the 2024 draft in the RAPS journal welcomed its risk- based control strategy but raised concern that release testing could lead to scrapping acceptable product; The revised text's explicit allowance for upstream controls alone, supported by risk analyses, engineering drawings and in-process data, responds to that concern. Trade coverage noted that injection depth is treated as user-dependent and outside the EDDC definition. The QMSR alignment matters because the regulation took effect in February 2026, and the Federal Register notice also asks for comment on the costs or savings the recommendations would produce.
Redica Recommendation
Combination product and delivery device manufacturers should re-map existing essential drug delivery output lists to the new performance-characteristic definition, check lot selection and preconditioning in verification protocols, and submit comments by January 28, 2027.
Reference document: Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products - Draft Guidance for Industry - October 2026 <RDR500019755>
4. Council Publishes Its Adopted Pharma Package Texts and Reasons Ahead of Parliament's Second Reading
Final | Pharma Legislation Reform
The Official Journal now carries the formally adopted first-reading texts with the Council's statements of reasons. Parliament's second- reading approval is the remaining step.
Substance
Positions (EU) No 11/2026 and No 12/2026, published on October 16 with the Council's statements of reasons, set out the adopted first- reading texts of the Directive replacing Directives 2001/83/EC and 2009/35/EC and the Regulation replacing Regulations (EC) No 141/2000, 726/2004 and 1901/2006. The Directive provides eight years of basic data protection and a maximum total protection period of eleven years, or twelve with the separate voucher, and allows Member States to request product launch and continued supply, with applicable market protection lost after three years of non-compliance, subject to exceptions. It extends the intellectual-property exception to procurement-tender applications, caps marketing-authorisation examination at 180 days, and lets pharmacies prepare magistral formulas up to seven days in advance, or three weeks where justified. The Regulation creates breakthrough orphan medicines with 11 years of market exclusivity against nine for regular orphans, requires shortage-prevention plans and supply-disruption notifications at least six months in advance, and limits the transferable data-protection voucher to five vouchers or 15 years with a EUR 490 million annual-sales restriction. Most provisions apply 24 months after entry into force, with shorter timelines for specified supply, sandbox, solidarity and voucher provisions.
Significance
The Council formally adopted these positions on September 28 after legal-linguistic revision, and the chair of Parliament's SANT committee has written that Parliament should approve them without amendment at second reading, so the published wording is the expected final text. CMS and other law firms reported a November plenary as the indicative date for that vote, after which the acts enter into force 20 days following their own Official Journal publication and the 24-month clock starts. The statements of reasons add detail that the September texts did not carry on their face, including the three-year non-compliance rule on supply, the EUR 490 million voucher cap and a three-year- and-six-month extension for specified Maltese authorisations based on United Kingdom authorisations. For sponsors, the practical change from September is certainty about the text.
Redica Recommendation
Regulatory, legal and supply teams should use the Official Journal texts as the working version for gap analysis, starting with Member State launch and supply requests, shortage-prevention plans and the six-month supply-disruption notice, ahead of Parliament's second reading.
Reference documents: Position (EU) No 11/2026 of the council at first reading with a view to the adoption of a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directives 2001/83/EC and 2009/35/EC <RDR500019290>, Position (EU) No 12/2026 of the Council at first reading with a view to the adoption of a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulations (EC) No 1394/2007 and (EU) No 536/2014 and repealing Regulations (EC) No 141/2000, (EC) No 726/2004 and (EC) No 1901/2006 <RDR500019292>, Statement of the Council's reasons: Position (EU) No 11/2026 of the Council at first reading with a view to the adoption of a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directives 2001/83/EC and 2009/35/EC <RDR500019291>, Statement of the Council's reasons: Position (EU) No 12/2026 of the Council at first reading with a view to the adoption of a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulations (EC) No 1394/2007 and (EU) No 536/2014 and repealing Regulations (EC) No 141/2000, (EC) No 726/2004 and (EC) No 1901/2006 <RDR500019294>
5. MHRA Sets 2030 Service Guarantees and an Adaptive Framework for AI Devices
Final | Regulatory Strategy
Planned 14-day first-in-human and 90-day licensing assessments anchor the strategy, while AI Airlock Phase 3 tests device lifecycle oversight. Strategy published October 14, 2026.
Substance
The MHRA Strategy 2030 introduces planned service guarantees of 14 days for initial first-in-human trial assessments, 90 days for first licensing assessments and 90 days for scientific opinions, alongside revised fees and eligible rebates. It expands continuous safety monitoring through linked health data and artificial intelligence, modernises Yellow Card reporting and device identification, and commits to structured digital product information by 2030 with accessible alternatives retained. It outlines earlier scientific advice, innovation sandboxes, coordinated access pathways and proportionate evidence approaches for rare diseases, advanced therapies and emerging technologies, and supports digital twins, synthetic data and human-relevant alternatives to animal models. For AI as a medical device, it proposes an adaptive framework with continuous performance monitoring, expanded predetermined change control plans, exploration of foundation-model master files and a Centre for Artificial Intelligence and Digital Health. Separately, the AI Airlock Phase 3 call published on October 6 prioritises post-market surveillance projects that capture how local infrastructure, data quality, workflows and user interaction affect device performance, and how updates, risks and rollbacks are communicated. Selected applicants receive simulation, virtual or real- world testing environments for 6 to 12 months, take part free of charge and fund their own testing and data access.
Significance
The strategy describes these guarantees as planned, so their start dates, fee levels and legal basis remain to be set, and the AI framework is presented as a proposal. RAPS and other trade outlets covered the launch on the day, the BioIndustry Association welcomed it, and the agency presented the AI device agenda at AdvaMed's annual conference within a week. The Airlock call came with the government's acceptance of all 44 recommendations of the National Commission into the Regulation of AI in Healthcare, and the programme is funded to April 2029, with the first Phase 3 innovators due to be selected in November 2026. The government's indefinite recognition of CE-marked devices, covered in entry 10, is presented in the MHRA's announcement as part of the same strategy's reliance aims.
Redica Recommendation
UK-facing sponsors should factor the planned 14-day and 90-day assessment guarantees into 2027 to 2030 launch sequencing, and AI device developers working on post-market monitoring should apply to AI Airlock Phase 3, which accepts applications on a rolling basis.
Reference document: MHRA Strategy 2030 <RDR500019220>, MHRA STRATEGY 2030: Executive Summary <RDR500019221>, AI Airlock Phase 3 application <RDR500018815>
6. PIC/S, EMA and WHO Issue a Joint Interpretation of the 2022 Sterile Annex 1
Final | GMP
A single reading of Annex 1 now covers contamination control strategy, PUPSIT, single-use systems and aseptic process simulation. In force since October 28, 2026.
Substance
PI 058-1 sets out question-and-answer interpretations of the most important changes in the 2022 Annex 1 to harmonise inspection and implementation, and states expressly that it introduces no new GMP requirements. On the contamination control strategy, it covers documented application to selected non-sterile processes, ongoing assessment of effectiveness, review at least annually, and risk mitigation while facilities are brought into compliance. It explains cleanroom qualification, material transfers, airflow protection, disinfection and barrier-system controls, and distinguishes vaporised hydrogen peroxide bio-decontamination from validated sterilisation. It details monitoring expectations for water for injection, sterilising steam and process gases, together with gowning qualification, aseptic behaviour and restrictions on unsupervised cleanroom access. It clarifies sterilisation validation, container-closure integrity, lyophilisation and pre-use post-sterilisation integrity testing, including the conditions for justified alternatives and the use of redundant filters. For closed and single- use systems it addresses supplier qualification, quality agreements, integrity testing, documented inspections and extractables and leachables assessed under representative manufacturing conditions. It also covers environmental monitoring, validation of rapid microbiological methods, aseptic process simulation design and frequency, recovery after failed simulations and microbiological quality- control testing.
Significance
The document was prepared by the PIC/S-EMA-WHO Annex 1 Joint Implementation Working Group, set up in January 2024, and formally adopted by all three bodies, so the same interpretation now sits behind EU GMP, the PIC/S GMP Guide and WHO prequalification inspections of sterile sites. Because the 2022 Annex 1 has applied since August 2023, the interpretations will be read against facilities and programs that inspectors have already been assessing for three years, and its guidance on risk mitigation while facilities are brought into compliance applies directly to sites still closing gaps. EMA hosted a stakeholder briefing webinar on October 22 ahead of the October 28 entry into force, GMP-Verlag and other trade outlets reported it the same week, and ECA Academy's Annex 1 conference in Vienna on November 3 to 6 put the document in front of sterile manufacturing specialists within days. National inspectorate Q&As on Annex 1, including Swissmedic's, now have a common reference to align with.
Redica Recommendation
Sterile manufacturers should review their contamination control strategy, PUPSIT justifications, single-use system qualification and aseptic process simulation programs against PI 058-1 before their next inspection by a PIC/S, EU or WHO prequalification inspectorate.
Reference documents: Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Products (2022) (Version 1) <RDR500019747>
7. EMA Drafts Methodological Rules for Platform Trials Meant to Support Approval
Draft | Clinical Trials
The draft reflection paper rejects response-adaptive randomisation and limits non-concurrent controls in confirmatory platform trials. Comments due January 31, 2027.
Substance
The draft reflection paper develops the framework proposed in EMA's 2022 concept paper and sets out methodological principles for platform trials intended to provide confirmatory evidence. It recommends early specification of objectives, estimands, testing strategies, analysis timing and criteria for adding or removing arms, and warns that inadequate planning may leave a trial exploratory. It recommends constant allocation ratios for each treatment comparison, rejects response-adaptive randomisation and generally discourages re- randomising participants. Concurrent controls are recommended, non-concurrent controls are generally limited to supplementary analyses or potentially secondary endpoints, and changing the control treatment for arms already enrolling is discouraged. The paper calls for prospective blinding and data-access arrangements, independent data monitoring and safeguards against disclosure of interim results. It explains when related hypotheses require strong family-wise error rate control, how shared controls affect the risk of simultaneous false- positive conclusions, power and sample size, and recommends evaluating operating characteristics across plausible platform scenarios, using simulation where needed.
Significance
CHMP adopted the draft for consultation on October 5, and EMA states that it complements its existing guidance on adaptive designs and multiplicity. RAPS covered the consultation in its European roundup, focusing on the treatment of family-wise error and multiple false- positive decisions in trials designed to support more than one regulatory decision. EMA has scheduled an ACT EU workshop on multiplicity in two-arm and platform trials for November 27, 2026, which its agenda describes as supporting finalisation of both the multiplicity guideline and this paper, so the workshop is the earliest public forum for testing positions before the comment deadline. Platforms that rely on response-adaptive randomisation or pooled non-concurrent controls would need design changes before their results could be presented as confirmatory evidence in an EU application.
Redica Recommendation
Sponsors running or planning master protocols intended to support EU marketing applications should test current designs against the paper's randomisation, control and error-control positions and submit comments by January 31, 2027.
Reference document: Draft Reflection paper on methodological aspects in confirmatory platform trials <RDR500019324>
8. China Drafts the Rules for Rare Disease and Pediatric Market Exclusivity
Draft | Market Exclusivity
Proposed terms run up to seven years for rare disease originators and two years for pediatric originators, with rare disease protection tied to supply. NMPA comments due November 18, 2026.
Substance
NMPA's draft measures propose market exclusivity for eligible rare disease and pediatric medicines, covering chemical drugs, therapeutic biological products and traditional Chinese medicines, with expert assessment for diseases outside the national rare disease catalogue. Rare disease periods would be seven years for qualifying innovative or overseas-marketed originators, five years for qualifying improved medicines and four years for specified first-in-China generic or biological approvals, running from marketing approval. Pediatric exclusivity would be two years for qualifying originators and one year for a first pediatric indication, child-appropriate dosage form or strength, which require pediatric clinical trials, and would start after any applicable data-protection period expires. Requests are filed and assessed with the registration application, only one exclusivity entitlement may be selected per application, and competing applications may be reviewed but not approved until protection expires. Protected rare disease medicines carry supply commitments and advance shortage-risk reporting, with early termination for failure to maintain supply. CDE's companion working procedure defines pediatric medicines as products for children under 16, requires supporting trials in Chinese children for the newer pediatric categories, and suspends the competing review clock after technical review, resuming 14 working days before exclusivity ends.
Significance
The measures implement Article 21 of the revised Implementing Regulations of the Drug Administration Law, in force since May 15, 2026, which introduced orphan and pediatric market exclusivity in China for the first time. Data-protection measures took effect the same day, but law firms had flagged through the summer that it was unclear how rare disease and pediatric products could apply for exclusivity until these rules appeared. Han Kun and other law firms published alerts on the October draft, noting that it also defines drugs of the same type to set the scope of protection. The supply condition is a material difference from a pure exclusivity grant, since a protected rare disease product can lose its term for failing to maintain supply, and the short comment windows of 15 days for CDE and one month for NMPA leave little time for coordinated industry input.
Redica Recommendation
Sponsors with rare disease or pediatric programs headed for China should model the proposed exclusivity periods against their data-protection terms and filing plans, and comment to CDE on its working procedure by November 7 and to NMPA on the measures by November 18, 2026.
Reference document: Implementing Measures for Drug Market Exclusivity (Draft for Comments) <RDR500019442>, Working Procedure for Drug Market Exclusivity (Draft for Comments) <RDR500019598>
9. FDA Extends Biosimilar Manufacturing Change Rules to Interchangeables in Final Q&A
Final | Biosimilars
Comparability assessments now weigh immunogenicity, and new dosage forms or strengths generally need prior approval. Final guidance in effect October 9, 2026.
Substance
The final guidance explains how holders of licensed biosimilars and interchangeable biosimilars should assess a manufacturing change's potential effect on product quality and select a prior approval supplement, changes being effected supplement or annual report. It recommends identifying the reporting category in CMC supplements, listing every change in the cover letter and including related labeling changes. Comparability rests on a risk-based exercise using analytical and stability data from prechange and postchange material, supported by process validation where appropriate, and a well-qualified in-house reference material with relevant historical data can support comparability without routinely requiring additional reference materials. The answer on reference materials now adds immunogenicity as a factor in judging whether comparability data are sufficient and reframes when reference product data should be used if prechange and postchange differences appear. Introducing a product into a multiproduct area or contract facility requires controls against cross-contamination and mix-ups. Supplements for a new dosage form or strength generally require prior approval and comparative analytical evidence against the reference product, and route-of-administration changes are now stated to be outside the guidance. The companion BPCI Act questions and answers, Revision 4, withdraws Q&A I.20 accordingly.
Significance
The final completes a BsUFA III commitment and replaces the July 2024 draft, with an introduction stating that the recommendations are intended to be consistent with ICH Q5E. Goodwin and other law firms noted that FDA had declined to extend Q&A I.20 to interchangeables when it was written because it had little experience with changes to those products, and has now concluded that the same principles apply. Comments on the 2024 draft from PhRMA, AHIP and others had asked FDA to confirm that comparability need only reference the biosimilar undergoing the change, and the revised reference-material answer addresses when reference product data enter the analysis. Cross-references now point to the finalized comparative analytical assessment guidance of September 2025, so supplements should cite the current documents.
Redica Recommendation
Biosimilar and interchangeable license holders should update change-control procedures to the final reporting categories, add immunogenicity to comparability sufficiency assessments, and stop citing Q&A I.20 of the BPCI Act questions and answers in supplements.
Reference documents: Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers - Guidance for Industry - October 2026 <RDR500019042>, Questions and Answers on Biosimilar Development and the BPCI Act - Guidance for Industry - October 2026 <RDR500019010>
10. Great Britain Will Recognize CE-Marked Medical Devices Indefinitely
Final | Market Access
EU MDR and IVDR certified devices keep access to Great Britain with no end date; MDD legacy devices follow EU timelines. Implementing legislation due before June 30, 2028.
Substance
The government response to the consultation held from February 16 to April 10, 2026, which drew 1,056 responses, confirms the intention to recognise indefinitely all CE-marked medical devices and IVDs certified under the EU MDR and IVDR, subject to the applicable domestic conditions for market access. Recognition of eligible devices certified under the Medical Devices Directive will align with EU transitional timelines, currently ending December 31, 2028, and devices lawfully placed on the EU or Great Britain market before that deadline may remain available. The government rejected the alternative of limiting recognition to devices with the same or lower Great Britain risk class and adding a separate reliance route for devices classed higher in Great Britain. The device component of combination products regulated as medical devices remains eligible, while Human Medicines Regulations requirements may still apply. Obligations for MHRA registration, a UK responsible person where required, English-language technical documentation and certificates, post-market surveillance and compliance with enforcement notices continue. UKCA marking remains available, and implementing legislation, subject to parliamentary approval, is to be in place before June 30, 2028.
Significance
CMS and other law firms published alerts on the day of the October 21 announcement, and the MHRA stated that more than 90 percent of devices registered for use in Great Britain carry a CE mark. MedTech Europe, ABHI and BIVDA issued a joint statement two days later welcoming the outcome and asking for clear implementation guidance. Consultancies including Emergo by UL noted that the decision removes the previously expected end date for MDR- and IVDR-compliant devices. CMS also pointed to government amendments to the Health Bill that would give the MHRA powers to develop a device licensing regime, so the recognition sits alongside a domestic framework still being built. Northern Ireland continues to apply the EU MDR and IVDR directly.
Redica Recommendation
Device manufacturers supplying Great Britain on CE certificates should keep MHRA registration, UK responsible person appointments and English-language documentation current, and plan the move off any MDD certificates against the EU transitional deadline of December 31, 2028.
Reference document: Government response to the targeted consultation on indefinite recognition of CE marked medical devices <RDR500019441>, MedTech Europe, ABHI and BIVDA welcome the indefinite recognition of CE-marked medical devices and IVDs in Great Britain <RDR500019590>
11. Australia Draws the Device Line for AI Digital Scribes
Final | Software as a Medical Device
TGA's revised guidance separates administrative scribe functions from regulated clinical functions, with eight worked examples and a CDSS exemption route. Updated guidance in effect October 16, 2026.
Substance
The updated guidance, replacing the January 30, 2026 version, widens the list of non-device functions beyond transcription and translation to organising information, summarising consultations, drafting clinical documentation, formatting information into structured fields for practitioner review and checking for incomplete administrative documentation. Functions that generate new clinical conclusions, diagnostic suggestions, treatment recommendations or autonomous clinical actions make a scribe a medical device. A new function-by-function table covers patient-history review, referral letters, record summaries, medical coding, reference information, AI chatbots and AI-generated insights, and eight examples include an autonomous agent that makes clinical decisions without practitioner review. Intended purpose must be consistent across labeling, instructions, advertising, websites and technical documentation, and disclaimers cannot override medical claims or therapeutic functionality. Regulatory status must be reassessed when features change, and foreseeable misuse should be addressed through design before relying on warnings. The guidance explains how a scribe may qualify for the existing clinical decision support system exemption, including notification and continuing safety and performance obligations. The companion CDSS guidance, updated the same day, adds digital scribes to its scope, removes references to artificial intelligence from the exemption criteria and notes it is under review for amendments taking effect November 1, 2026.
Significance
TGA published the update with the outcomes of its targeted review of digital scribes: None of the 12 suppliers reviewed identified its product as a medical device, but TGA found likely device functions in eight of them, after an environmental scan in 2025 identified about 100 suppliers in Australia. Pure Global and other consultancies covered the release, and law firms had tracked TGA's position since its first information notice in August 2025. The CDSS exemption criteria now state that recommendations must be transparent and independently verifiable, so opaque systems fail the exemption whatever technique they use, which narrows the route for scribes whose outputs cannot be traced to supporting logic. TGA has said it will apply proportional compliance, and the review gives it a documented basis for follow-up with suppliers whose products cross the line.
Redica Recommendation
Suppliers of AI scribes in Australia should map each feature against the TGA function table, confirm that labeling, websites and advertising match the intended purpose, and decide between ARTG inclusion and the CDSS exemption with its notification duty.
Reference document: Digital scribes (October 2026) <RDR500019285>, Understanding clinical decision support system software regulation (October 2026) <RDR500019284>
12. Health Canada Finalizes Its Revised Device Establishment Licensing Guidance for December 1
Final | Licensing & Authorisation
GUI-0016 Version 11 moves applications to the form's Submit function and lists documented procedures by activity and device class. Takes effect December 1, 2026.
Substance
Version 11 of GUI-0016 finalizes the June 2026 draft with an effective date of December 1, 2026. It explains who needs a Medical Device Establishment Licence, identifying importation and distribution as the licensable activities, including distribution of a manufacturer's own Class I devices, and describes exemptions for specified manufacturers, retailers and foreign distributors supplying licensed Canadian importers. Applications are now sent using the Submit function of the form instead of by email, and completeness screening is reduced to two criteria: All relevant sections complete and all indicated documents present. A new section lists the documented procedures required of importers, distributors and Class I manufacturers by activity and device class, and an expanded Sites subsection states that third-party logistics providers may qualify as sites and sets obligations where a site is a different legal entity from the licence holder. The senior official is now described as completing section 6 of the form, where the prior version said signing, and small business fee reductions require that the applicant already hold small business status. The 120-calendar-day service standard, annual license review before April 1 and 15-day notification of specified changes continue.
Significance
The guidance implements the amended Medical Devices Regulations published in Canada Gazette, Part II on June 17, 2026, and earlier communications had pointed to December 14, 2026, so the final's December 1 date moves the start forward by two weeks. Torys and other law firms noted that the amendments also created an MDEL exemption for foreign distributors, which this version describes. Health Canada's compliance bulletin on the second phase of licensing modernization reported that it cancelled 145 licences after holders missed the April 1, 2024 annual review, which shows how the agency enforces the review date the guidance restates. Emergo by UL and other consultancies tracked the update with the companion form and guidance changes, and the documented-procedure list gives inspectors a fixed checklist against which to assess establishments.
Redica Recommendation
Importers, distributors and Class I manufacturers holding or seeking an MDEL should check their documented procedures and third-party logistics sites against Version 11 before December 1, 2026, and keep the April 1 annual licence review on their calendars.
Reference document: Guidance on medical device establishment licensing (GUI-0016) (Version 11) <RDR500019827>

Appendix
Section 1
- Regulatory Considerations for Prescription Drug Use Related Software - Guidance for Industry - October 2026 <RDR500019394>
Section 2
- Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management - Draft Guidance for Industry - October 2026 <RDR500019689>
Section 3
- Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products - Draft Guidance for Industry - October 2026 <RDR500019755>
Section 4
- Position (EU) No 11/2026 of the council at first reading with a view to the adoption of a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directives 2001/83/EC and 2009/35/EC <RDR500019290>
- Position (EU) No 12/2026 of the Council at first reading with a view to the adoption of a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulations (EC) No 1394/2007 and (EU) No 536/2014 and repealing Regulations (EC) No 141/2000, (EC) No 726/2004 and (EC) No 1901/2006 <RDR500019292>
- Statement of the Council's reasons: Position (EU) No 11/2026 of the Council at first reading with a view to the adoption of a Directive of the European Parliament and of the Council on the Union code relating to medicinal products for human use, and repealing Directives 2001/83/EC and 2009/35/EC <RDR500019291>
- Statement of the Council's reasons: Position (EU) No 12/2026 of the Council at first reading with a view to the adoption of a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulations (EC) No 1394/2007 and (EU) No 536/2014 and repealing Regulations (EC) No 141/2000, (EC) No 726/2004 and (EC) No 1901/2006 <RDR500019294>
Section 5
- MHRA Strategy 2030 <RDR500019220>
- MHRA STRATEGY 2030: Executive Summary <RDR500019221>
- AI Airlock Phase 3 application <RDR500018815>
Section 6
- Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Products (2022) (Version 1) <RDR500019747>
Section 7
- Draft Reflection paper on methodological aspects in confirmatory platform trials <RDR500019324>
Section 8
- Implementing Measures for Drug Market Exclusivity (Draft for Comments) <RDR500019442>
- Working Procedure for Drug Market Exclusivity (Draft for Comments) <RDR500019598>
Section 9
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers - Guidance for Industry - October 2026 <RDR500019042>
- Questions and Answers on Biosimilar Development and the BPCI Act - Guidance for Industry - October 2026 <RDR500019010>
Section 10
- Government response to the targeted consultation on indefinite recognition of CE marked medical devices <RDR500019441>
- MedTech Europe, ABHI and BIVDA welcome the indefinite recognition of CE-marked medical devices and IVDs in Great Britain <RDR500019590>
Section 11
- Digital scribes (October 2026) <RDR500019285>
- Understanding clinical decision support system software regulation (October 2026) <RDR500019284>
Section 12
- Guidance on medical device establishment licensing (GUI-0016) (Version 11) <RDR500019827>
来源:Redica GMP 检查与质量分析 · redica.com